Boehringer Ingelheim Plans Biopharmaceuticals Facility in China - - BioPharm International

ADVERTISEMENT

Boehringer Ingelheim Plans Biopharmaceuticals Facility in China


Boehringer Ingelheim signed an alliance agreement and contract to build a cGMP biopharmaceuticals facility with Zhangjiang Biotech & Pharmaceutical Base Development Company (ZJ Base Company) in Pudong, Shanghai, the company announced in a press release. The new site will provide a full range of development and clinical services to Chinese and multinational customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China using mammalian cell-culture technology, the company claimed.

The facility will include technical process development and cGMP manufacturing and will be ready for operation in early 2016.
 “Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high-quality biopharmaceuticals in China,” stated Christian Boehringer, chairman of the Shareholders Committee, in the press release.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines

Click here